Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This is a single center, nonrandom, open-label study aiming to evluate the efficacy and
safety of lenvatinib for patients with pretreated advanced biliary tract cancer.